WuXi Healthcare Forum 2019

Speakers

Ge Li

Chairman at WuXi AppTec Group

Dr. Ge Li is one of the most influential leaders in the global biopharma R&D industry. He pioneered an integrated R&D service model and the open-acces...

Ruilin Song

Executive President at China Pharmaceutical Innovation and Research Development Association

Mr. Song Ruilin, L.L.B. from China University of Political Science and Law, EMBA from China Europe International Business School, Doctor of Social and...

Steve Bates

CEO of UK BioIndustry Association

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve sought to make the UK life science ecosystem the third global c...

Leon Wang

Executive Vice President International and China President at AstraZeneca

Leon Wang is Executive Vice President, International and China President at AstraZeneca. He is responsible for the overall strategy for the region and...

Edward Hu

Co-CEO of WuXi AppTec

Mr. Edward Hu is currently Co-CEO at WuXi AppTec. With experience in operational excellence, financial management and global business expansion, Mr. H...

Kevin Holland

Minister-Counsellor and Director of Life Sciences, Healthcare and Social Care for China at British Embassy

Kevin Holland is a Senior Business Executive with twenty-five years' international experience building sustainable, high growth pharmaceutical, biotec...

Lianshan Zhang

President of Global R&D at Jiangsu Hengrui Medicine

Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as t...

Leon Chen

CEO & Founding Partner of 6 Dimensions Capital

Leon Chen is the Founder and Founding Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (...

George Chen

Sr. VP, Global R&D Oncology Unit; Head, R&D China at AstraZeneca

Dr. George Chen currently serves as a Sr VP of Global R&D Oncology and Head of R&D China, which he built from scratch, at AstraZeneca. Dr. George Chen...

Damian O’Connell

CEO Experimental Drug Development Centre of A*STAR

Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Clinical Science...

Steve Yang

EVP, CBO at WuXi AppTec

Dr. Steve Yang is Executive Vice President and Chief Business Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His respons...

David Ho

Scientific Director & CEO of Aaron Diamond AIDS Research Center

David D. Ho is the founding Scientific Director of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at The Rockefeller Universit...

Zhijian ‘James’ Chen

George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern Medical Center

Zhijian ‘James’ Chen is an Investigator of Howard Hughes Medical Institute, and Professor in the Department of Molecular Biology at the University of ...

Jane Osbourn

Chair of UK BioIndustry Association, Vice President R&D at MedImmune

Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An...

Michael Yi

Partner at Hillhouse Capital Group

Michael Yi is a Partner at Hillhouse Capital Group. He has been working with Hillhouse since the inception of the firm. Mr.Yi leads Hillhouse Capital’...

Nisa Leung

Managing Partner at Qiming Venture Partners

Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming currently manages over USD 4.3 billion in ass...

Ken Drazan

Co-founder and CEO of Arsenal Bio

Ken is the CEO and co-founder of Arsenal Bio a startup focused on synthetic control of the immune system which is based in San Francisco and Los Angel...

Ruyi He

Chief Medical Officer at State Development and Investment Corporation （SDIC）

Dr. Ruyi He was the Chief Scientist at the Center for Drug Evaluation, the Chinese Food and Drug Administration (CFDA) and fully participated the refo...

John Oyler

Chairman, Co-Founder & CEO of BeiGene

John V. Oyler is the Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, comm...

Gang Wang

Vice President for Quality and Global Regulatory Affairs at WuXi Biologics

Dr. Wang Gang is Vice President for Quality (Shanghai) and Global Regulatory Affairs of WuXi Biologics (WuXi). Prior to joining WuXi, Dr. Wang was Chi...

Chiang Syin

Chief Quality Oﬃcer at WuXi Biologics

辛强博士于2018年1月加入药明生物担任首席质量官，在此之前他在美国FDA任职近30年，在生物制品及生物技术药物的CMC（生产过程与控制）和GMP（药...

Craig Anderson

Professor at University of New South Wales in Sydney, Executive Director at The George Institute for Global Health in China

Dr. Anderson is Executive Director of The George Institute for Global Health in China, Senior Principal Research Fellow of the National Health and Med...

Zhengqing Li

VP and Head of China Development at MSD

Zhengqing is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of Merck’s R&...

Matt Cooper

Exec Director - Business Development & Marketing of The National Institute for Health Research, UK

The National Institute for Health Research Clinical Research Network is the research delivery arm of the NHS. It invests some £300m each year into an...

Carl Firth

Chief Executive Officer at ASLAN Pharmaceuticals

Dr Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Dr Firth founded ASLAN in 2010 after a career in global pharmaceutical ...

Jinzi J. Wu

Founder, Chairman and CEO of Ascletis Pharma

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with two commer...

James Xue

Chairman and CEO of CANbridge Pharmaceuticals

Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company ...

Alex Zhavoronkov

Founder and CEO of Insilico Medicine

Dr. Zhavoronkov is the CEO of Insilico Medicine, a leader in the next-generation artificial intelligence technologies for drug discovery, biomarker de...

Eric Morgen

COO and CMO at BIOAGE

Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously a...

Sang Hoon Lee

Founder and CEO of ABL Bio

Sang Hoon Lee is the founder and CEO of ABL Bio. Prior to creating ABL Bio, Sang Hoon Lee served as the head of the Bio Division at Hanwha Chemical fr...

Zhenyu Ju

Dean at Institute of Aging and Regenerative Medicine, Jinan University

Research Interests:Molecular mechanisms of stem cell aging and tissue regeneration, and their effects on longevityResearch projects:Undergoing: 2 Nati...

Guy Spigelman

VP Portfolio Success at aMoon Fund

Guy Spigelman is VP of Portfolio Success at aMoon, a Global HealthTech and LifeSciences VC based in Israel with over $800M under management. Previousl...

Ash Bahl

CSO and Head of R&D at Carrick Therapeutics

Dr. Bahl has 25 years of international Pharmaceutical experience working to deliver innovation via drug development projects in the US, Japan, and Eur...

Binghe Xu

Director of Department of Medical Oncology at the National Cancer Center, China

Dr. Binghe Xu is Professor and Director of the Department of Medical Oncology at the National Cancer Center (NCC) / Cancer Hospital, Chinese Academy o...

Karen Reeves

President and CMO at AZTherapies

Karen Reeves, MD is President and Chief Medical Officer at AZTherapies, a start-up company using a multi-action approach to treat Alzheimer’s Disease ...

Zhengying Pan

Associate Professor at School of Chemical Biology & Biotechnology, Peking University

1994年毕业于北京大学化学系，1999年获得美国哥伦比亚大学博士学位（导师：Clark Still教授），2002年在斯坦福大学完成博士后研究（导师...

Simone Botti

CEO of MetaboMed

Dr. Botti has been Metabomed's CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, w...

Sofie Qiao

President and CEO of Vivace Therapeutics

Dr. Sofie Qiao is the founding president and CEO of Vivace Therapeutics. Prior to co-founding Vivace, she served as managing director of WuXi ventures...

Darren Ji

Co-founder and CEO of Elpiscience Biopharmaceutical

Darren is co-founder and CEO of Elpiscience Biopharmaceuticals。 He is also a Venture Partner of Lilly Asia Ventures (LAV)., Inc. Prior to that Darren ...

Yanni Lin

CTO at CureGenetics

Yanni Lin is the Chief Technology Officer and co-founder of Cure Genetics Co., Ltd. She is passionate about using genome engineering to create clinica...

Jörg Weiser

Managing Director of Schrödinger

Dr. Weiser joined Schrödinger in 2002. He received his doctorate in Organic Chemistry from the Georg-August-University in Göttingen, Germany in 1996. ...

Misti Ushio

CEO of TARA Biosystem

Misti Ushio is the CEO of TARA Biosystems.TARA Biosystems develops physiologically relevant 3D tissue models for drug discovery and development applic...

Qi Liu

Professor at Bioinformatics Department, Tongji University

Prof Qi Liu is now the professor in Bioinformatics Department in Tongji University. He has been actively applying AI techniques for drug discovery, tu...

Naheed Kurji

President & Chief Executive Officer at Cyclica

Naheed Kurji is the President and CEO of Cyclica, a Toronto-based, venture-backed biotechnology company that has recently been named by Deep Knowledge...

Willliam R. Keller

Chairman at Coland Pharmaceuticals

Willliam Robert Keller joined Roche in Basel 1972 and served from 1974 to 2003 in several marketing and General Manager positions at Roche Group in So...

Li Chen

CEO of Hua Medicine

Dr. Li Chen, Chairman, Founder, Chief Executive Officer, and Chief Scientific Officer. leads Hua Medicine a clinical stage biotech company whose missi...

Chris Chen

Chief Executive Officer at WuXi Biologics

Dr. Chris Chen is currently Chief Executive Officer at WuXi Biologics, a Hong Kong listed public company with market cap of approx $10+ billion USD. A...

Ray Tabibiazar

Senior Vice President at Twist Bioscience

Ray is a seasoned executive, bringing his unique perspective as a clinician-scientist leading and growing start-up companies. He joins Twist Bioscienc...

Dan Wang

Head at Johnson & Johnson Innovation, Asia Pacific

Dan Wang, MD, is the Head of Johnson & Johnson Innovation, Asia Pacific. In this role, she is responsible for managing a portfolio of co-investments s...

Curtis Keith

Chief Scientific Officer at Harvard University’s Blavatnik Biomedical Accelerator

Dr. Curtis Keith has served as Chief Scientific Officer of Harvard University’s Blavatnik Biomedical Accelerator (previously, Harvard Biomedical Accel...

Robert S. Sullivan

Dean at Rady School of Management, UC San Diego

Robert S. Sullivan joined the Rady School of Management at UC San Diego as its founding dean in January 2003. Dr. Sullivan is an expert on entrepreneu...

Jonathan Wang

Partner at OrbiMed

Dr. Jonathan Wang is a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm, where he founded OrbiMed Asia. He is a HKEX Biot...

Toshio Fujimoto

General Manager of Shonan Health Innovation Park at Takeda

Toshio Fujimoto, MD, MBA, is the General Manager of Shonan Health Innovation Park (iPark), a science park launched by Takeda Pharmaceutical Company Lt...

Sophie Sun

Managing Director of Merck Innovation Hub China

Sophie Sun is currently Managing Director of Merck China Innovation Hub and Vice President of Merck Strategy and Transformation China. In this role, s...

Ken Hitchner

Chairman and CEO, Asia Pacific Ex-Japan of Goldman Sachs (Asia) L.L.C.

Ken is chairman and chief executive officer of Goldman Sachs in Asia PacificEx-Japan. He is a member of the firm’s Management Committee and co-chairs ...

Yibing Wu

Joint Head, Enterprise Development Group & Head, China at Temasek

Mr. Wu joined Temasek in October 2013 and is currently Joint Head, Enterprise Development Group and Head, China.Mr. Wu was previously President of CIT...

Andy Lin

Founding Partner at Loyal Valley Capital

Andy Lin is an experienced entrepreneur, accomplished investor and dedicated philanthropist in China.Mr. Andy Lin founded Loyal Valley Capital (“LVC”)...

Greg Scott

Founder and CEO of ChinaBio

Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC...

Lee Ligang Zhang

Founder, Chairman and CEO of iKang Healthcare Group

Mr. Lee Ligang Zhang has been a successful serial entrepreneur and business executive since he dropped out from graduate school at Harvard University ...

Shuyang Zhang

Vice President at Peking Union Medical College Hospital

心血管内科主任医师教授博士生导师北京协和医院副院长中国医学科学院北京协和医学院副院校长国务院政府特殊津贴专家国家卫生计生突出贡献中青年专...

John Cai

Director of Center for Healthcare Management and Policy, Adjunct Professor of Economics at China Europe International Business School (CEIBS)

Prof. Cai is the Director of Center for Healthcare Management and Policy and Adjunct Professor of Economics at China Europe International Business Sch...

Feng Deng

Founding Managing Director of Northern Light Venture Capital

Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He currently manages over US$ 4.5 billion with 5 US$ funds and 5 RMB funds. He ha...

Rong Yu

Chairman at Meinian Onehealth Healthcare Group

Born in 1971, graduated from Shanghai Jiaotong University with Bachelor’s degree in Electronic Engineering, Shanghai University of Finance and Economi...

Bin Li

Partner and Managing Director of Ally Bridge Group

Dr. Bin Li is the founder and Chief Investment Officer of Ally Bridge LB Healthcare Fund and a partner of Ally Bridge Group. Previously, he was a Mana...

Wilson Zhang

Chief Strategy Officer & SVP at WuXi AppTec

After completing pre-med at Peking University, Dr. Zhang earned M.D. from Peking Union Medical College. Then, received Ph.D. in Health Policy from Har...

Wenhao Zhou

VP at Children’s Hospital of Fudan University

周文浩，临床医学博士，主任医师，教授，博士生导师。现任中华医学会儿科分会新生儿学组副组长等职。先后入选教育部“新世纪优秀人才”、“上海市领军人才”、“...

Gang Chen

CEO of WeGene

Dr. Gang CHEN is a co-founder and the CEO of WeGene, which is a leading direct-to-consumer genetic testing and population genomics company in China. D...

Kai Wang

Founder and CEO of OrigiMed

Dr. Kai Wang is the Founder and CEO of OrigiMed, a medical science and technology transforming company which devotes to provide comprehensive molecula...

Ning Guang

Vice President at Ruijin Hospital of Shanghai Jiaotong University

Guang Ning, M.D., Ph.D., he is Director of Shanghai Institute of Endocrine and Metabolic Diseases, Head of Shanghai Clinical Center for Endocrine and ...

Sijia Lu

CEO of Yikon Genomics

陆思嘉博士毕业于美国哈佛大学，高通量基因测序专家，MALBAC全基因组扩增技术共同发明人，江苏省“双创计划”引进人才，上海市人大代表，上海市“千人计划...

William Morice

President at Mayo Clinic Laboratories

Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester. President, Mayo Clinic Laboratories.Research interests: Lymphoprolifer...

Daozhi Liu

Founding Partner at Sunland Capital

发起创办山蓝资本，具有医疗专业基金发起、募资、团队组建、投资、投资后管理等全过程管理经验；具有整个医疗企业创业全过程成功经验：上海微创医疗器械（集团）...

Martien van Osch

Managing Partner at Forbion

Martien is a Managing Partner at Forbion, a leading European venture capital firm that works closely with entrepreneurs to build life sciences compani...

Yaoyi Zhu

Chairman at IVD Branch, China Association for Medical Devices Industry

1991.02-1999.4Manager, Beckman Coulter1999.07-2003.02 GM of Diagnostic Division, Shanghai Fosun Pharma2003.03-2016.12VP & CEO of Diagnostics Division...

Jason Liu

CEO of WuXi Diagnostics

Dr. Jason Liu is a seasoned executive with nearly 30 years of experience in life science industry, including 20 years of senior leadership in multinat...

Stanley Li

Chairman and President at DXY

哈尔滨医科大学临床医学本科毕业哈尔滨医科大学肿瘤免疫学硕士毕业2000年创办丁香园，2006年放弃博士学位全职创业。所获荣誉：浙江省健康服务业促进会副...

Tony Zhang

Founder & CEO of LinkDoc

Worked in product teams of Tencent and Alibaba for xx years and then founded LinkDoc in 2014 as CEO.Built LinkDoc into the largest and NLP technology ...

Andy A. Liu

CEO of CW Data Technologies

Mr. Andy A. Liu is the CEO of CW Data Technologies. (中电药明数据科技)CW Data is a ...

Hong Li

Vice President at Digital China Health Technologies

Dr. Li currently is Vice President, Digital China Health Technologies Corp Limited. He is also an Adjunct Associate Professor of Cincinnati University...

Xiaodong Tao

CEO of iFlytek Healthcare

Xiaodong Tao, who got a Ph.D from Johns Hopkins University after graduated from the Department of Electronic Engineering and Information Science of Un...

Xinxin Gao

CEO and Founding Partner of Jiangmen

Ms. Gao Xinxin is CEO and founding partner of Jiangmen, a venture capital focusing on discovering, accelerating and investing in startups leveraging i...

Fay Xing

CEO of PICA Health

Fay XING is the CEO of Pica Health, a digital health company that was incubated at Wuxi Healthcare Ventures. Pica is committed to empower Chinese phys...

Ning Hou

COO at XiKang

Hou Ning, Senior Vice President and Chief Operating Officer of Neusoft Xikang Health Technology Co., Ltd., is mainly responsible for the business cons...

Meng Zhang

General Manager at Tencent Health

张猛，腾讯医疗副总裁。凭借对医疗行业深厚的热忱和经验，张猛于2016年12月加入腾讯，主要负责数字化医疗创新项目的孵化，目前已成功打造一款全新医学科普...

Mr. Song Ruilin, L.L.B. from China University of Political Science and Law, EMBA from China Europe International Business School, Doctor of Social and Administrative Pharmacy, China Pharmaceutical University, is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA); Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University. Mr. Song was former Deputy Director-General of the Department of Education, Science, Culture and Public Health in Legislative Affairs Office at State Council of China. He engaged in health and drug policy and legal studies for a long time, especially in optimizing the reform of drug review and approval system, medical insurance reimbursement system and making policies for pharmaceutical innovation in China.
Currently, Mr. Song also undertakes several social positions, such as Biotech Advisory Panel Member for the Stock Exchange of Hong Kong Limited, Vice President of China Alliance for Rare Disease (CARD), Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Standing Director of China Chamber of International Commerce (CCOIC) and Director of Chinese Pharmaceutical Association (CPA).

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve sought to make the UK life science ecosystem the third global cluster.
He led the major BIA campaign to improved access to finance for members through the refilling of the Biomedical Catalyst. He has been an influential figure on the sector’s approach to Brexit securing key industry asks in the UK government’s political declaration on its future relationship with the EU. Steve has championed the need for new anti-microbial resistance agents, the companies that develop them and for this to be on the global agenda. Steve advocates for the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
Steve worked to develop the UK’s Life Science Sector Deal as part of the UK Government’s Industrial Strategy. He has grown the reach and membership of the BIA to include the UK’s engineering biology, Genomics and AI and digital health communities whilst increasing the participation of global leading players in the Association.Steve attends the UK’s Life Science Council and sat on The Royal Society's Science, Industry and Translation Committee 2016-2018 and the Science Media Centre Advisory Board.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is vice chair of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Leon Wang is Executive Vice President, International and China President at AstraZeneca. He is responsible for the overall strategy for the region and for driving sustainable growth across our activities in China, Asia Area, Australia, New Zealand, as well as Latin America, Brazil, Russia, Eurasia, the Middle East and Africa. As a member of AstraZeneca’s Senior Executive Team, Leon reports to the CEO, Pascal Soriot.
Leon joined AstraZeneca China in March 2013 as Vice President for GI, Respiratory, Anaesthesia and Anti-infection (GRA), and was promoted to President of AstraZeneca China in 2014. Under Leon’s leadership, China has become AstraZeneca’s second-largest market worldwide, and AstraZeneca has become the second largest and the fastest-growing multinational pharmaceutical company in China. In January 2017, Leon was promoted to Executive Vice President, Asia Pacific Region at AstraZeneca, with responsibility for the strategy and sustainable growth of businesses in China, Asia Area, Australia and New Zealand.
As a local leader, Leon grew up, studied, and developed his career in Shanghai, and he is devoted to the long-term development of AstraZeneca’s business in China as well as the nation’s pharmaceutical industry.
During his tenure, Leon has advocated and driven the commercial innovation strategy in China. Focusing on the core company value of ‘Putting Patients First’, he has led the company’s efforts to establish strategic collaboration with cross-border partners, to provide innovative integrated diagnosis-and-treatment solution covering the entire patient journey and help for establishing an innovative healthcare ecosystem in the industry.
With twenty years of extensive management experience in the pharmaceutical industry, including a series of positions of increasing responsibility in marketing and business leadership at Roche, where he was a Business Unit Vice President before joining AstraZeneca, Leon has developed deep and unique insights into China’s healthcare and pharmaceutical industries.
In addition, Leon holds several positions in local trade associations and other prominent organizations. These include Member of the 12th Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference, Deputy to the 16th Wuxi Municipal People’s Congress, Senior Vice President of China Pharmaceutical Enterprise Association, Vice Chairman of the 7th Council of the Shanghai Association of Enterprises with Foreign Investment.
Leon holds an EMBA from China Europe International Business School, and a Bachelor of Arts from Shanghai International Studies University.

Mr. Edward Hu is currently Co-CEO at WuXi AppTec. With experience in operational excellence, financial management and global business expansion, Mr. Hu has demonstrated his extraordinary leadership to help the business expand further.
Since joined WuXi in 2007, Mr. Hu has served as the company’s Chief Operating Officer, and later Chief Financial Officer and Chief Investment Officer. Over the past decade, he has scored significant achievements in WuXi’s rapid development. Mr. Hu was elected to the Board of Directors in March 2016.
Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master’s degree in Chemistry from Carnegie Mellon University.

Kevin Holland is a Senior Business Executive with twenty-five years' international experience building sustainable, high growth pharmaceutical, biotechnology and medical device businesses across Europe and Emerging Markets and leading R&D programs through to commercialisation.
In 2016, relocated to China as Minister-Counsellor and Director of Life Sciences, Healthcare and Social Care for China, based in the British Embassy in Beijing. As a commercial diplomat, he is responsible for sourcing China based investment into UK life and health companies and for increasing trade opportunities and market access for UK companies into China.
From 1999 to 2014, he worked for Baxter - a US-listed global healthcare leader in chronic and severe diseases - where he managed teams and P&L across forty countries. As Region Head, he was directly responsible for all Baxter’s businesses in Russia, Turkey, Middle East, Africa, Israel and CIS, successfully building a high growth, compliance-focused $600m region employing >1500 people.
He led extensive business development and growth activities with governments and private partners across EMEA and also served as Vice President Market Access EMEA in Switzerland, General Manager Middle East and Africa in Dubai, Business Unit Director Nordic in Sweden and Director of Strategy Europe in Belgium.
From 1987 to 1997, Kevin held European R&D management positions at Unilever, in charge of innovation, industrialisation and commercialisation for speciality chemicals.

Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of innovative pipeline across all the therapeutic areas in the company. Prior to Hengrui, he was a senior research executive at Marcadia Biotech. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide/protein therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.
Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. (summa cum laude) in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University.

Leon Chen is the Founder and Founding Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital - one of the largest healthcare focused investment group with unique capability and extensive coverage across China and the US. Dr. Leon Chen became 6 Dimensions Capital’s Founding Partner & CEO. Before founding Frontline BioVentures in 2012, Leon was a Partner with Fidelity Growth Partners Asia, and a Managing Partner with BioVeda China. Since 2005, Leon has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, TenNor Therapeutics, MDDF, Coherent Biopharma, Yikon Genomics, Huazhou, Bio Kangtai and Neusoft Medical.
Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies; past affiliations include McKinsey & Company, Ernst & Young LLP.
Leon also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
He received a BS degree from Peking University, a Ph.D. degree with top honor from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.

Dr. George Chen currently serves as a Sr VP of Global R&D Oncology and Head of R&D China, which he built from scratch, at AstraZeneca. Dr. George Chen is an accomplished pharmaceutical R&D executive with over 15 years of industry experience in clinical development, medical affairs, strategic planning and business development. Prior to joining AstraZeneca, Dr. Chen was the founding Chief Medical Officer at BeiGene, a China based global biotech focusing on oncology drug research and development.
Dr. Chen started his pharmaceutical industry career with Eli Lilly, where he served as a Strategy Advisor for Corporate Strategic Assets Management and Business Development and as a Global Medical Advisor for Global Oncology Platform Team, respectively. After his tenure at Eli Lilly, Dr. Chen joined GSK as the Chief Medical Officer and Head of Development for GSK’s Great China Area responsible for clinical development, medical affairs and China portfolio management, and then as a Global Medicine Development Leader (MDL) with GSK’s Global Oncology in Collegeville of Pennsylvania, USA. Later on, he joined JnJ Pharmaceutical R&D (JJPRD) as a VP/Head of Compound Development Teams for Asia. Dr. Chen has deep experience and knowledge in drug development with a proven track record of building and leading high performance development teams and getting IND and NDA approvals.
Prior to his career in pharmaceutical industry, Dr. Chen was a Senior Staff Scientist and Investigator at NIH in Bethesda of Maryland, USA. Dr Chen received his medical degree from Shanghai Medical College of Fudan University and his MBA from the Wharton School of University of Pennsylvania. He had his post graduate medical training in oncology at Shanghai Cancer Hospital and New York Medical College, respectively. Dr. Chen is also well published in oncology and immunology on international peer reviewed journals.

Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Clinical Sciences (CS) is a global organization (based Germany, US, Japan, China) with responsibility for the first use of drug products in humans up to Proof of Concept, as well as all clinical pharmacological components of NDAs.
Damian previously has held senior positions within Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals & Neurex. Damian, has both MD & PhD degrees from the National University of Ireland, has been a Medical Faculty member of The University of Virginia Health Sciences Center as well as being a member of the Clinical Pharmacology & Therapeutics Department at University College Cork, Ireland where he was a Professor of Clinical Research. He started his career in the Industry in 1998.
Damian is a member of the Faculty of Pharmaceutical Medicine; Fellow of The Royal Society of Medicine; Fellow of The Royal Academy of Medicine (Ireland); Member of the British Pharmacological Society; Member of the Drug Safety Executive Council (DSEC); Member American Society for Clinical Pharmacology and Therapeutics; Member American College of Clinical Pharmacology; Member of American Society of Pharmacometrics; Member of the Irish Association of Pharmacologists; Member of the Irish Cardiac Society; Member of the British Hypertension Society.

Dr. Steve Yang is Executive Vice President and Chief Business Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His responsibilities include management of multiple business units and commercial operation. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China, US, and Europe.
Dr. Yang is a pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.

David D. Ho is the founding Scientific Director of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at The Rockefeller University. He received his degrees from California Institute of Technology (1974) and Harvard Medical School (1978).
Dr. Ho has been at the forefront of AIDS research for 38 years, publishing over 400 papers. His elegant studies unveiled the dynamic nature of HIV replication in vivo and revolutionized our basic understanding of this horrific disease. This knowledge led him to champion combination antiretroviral therapy that resulted in unprecedented control of HIV in patients. An automatic death sentence has been transformed into a manageable disease, and over 20 million worldwide are currently on such therapy. Dr. Ho’s research team is now devoting considerable efforts on vaccine and antibody research in order to halt or slow the spread of the AIDS epidemic.
Dr. Ho has received numerous honors and awards, including fourteen honorary doctorates. He was named Time Magazine’s Man of the Year in 1996 and the recipient of a Presidential Medal from Bill Clinton in 2001. He was also inducted into the California Hall of Fame. Dr. Ho was also recognized by the Kingdom of Thailand with the Prince Mahidol Award in Medicine, and recently given the Distinguished Alumni Award by Caltech. He is a member of the US National Academy of Medicine as well as the Chinese Academy of Engineering. Dr. Ho is also a founder of several successful biotechnology companies.

Zhijian ‘James’ Chen is an Investigator of Howard Hughes Medical Institute, and Professor in the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas. He is also Director of Inflammation Research Center and George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern. Prior to moving to Dallas, Chen was a senior scientist at ProScript Inc. where he helped discover the proteasome inhibitor VELCADE, a medicine used for the treatment of multiple myeloma. After joining UT Southwestern in 1997, Chen discovered the regulatory role of ubiquitination in protein kinase activation in the NF-B and MAP kinase pathways. In addition, he discovered the Mitochondrial Antiviral Signaling (MAVS) protein that reveals a new role of mitochondria in immunity. More recently, Chen discovered cyclic GMP-AMP synthase (cGAS) as a cytosolic DNA sensor and a new cyclic di-nucleotide signaling pathway that mediate innate immune responses in animal cells. For his work, Chen has received numerous honors including the National Academy of Science Award in Molecular Biology (2012), the American Society of Biochemistry and Molecular Biology (ASBMB) Merck Award (2015), the Lurie Prize in Biomedical Sciences from the Foundation of NIH (2018) and the Breakthrough Prize in Life Sciences (2019). Chen is a member of the National Academy of Sciences.

Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of a number of marketed drugs and more than 40 clinical candidates. She has worked across many therapy areas and currently leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies. Jane is also Site Leader for MedImmune’s facility in Cambridge UK, which is home to over 550 MedImmune employees, and chairs the cross-campus leadership team for AstraZeneca in Cambridge.
Jane obtained a First Class degree in Biochemistry from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a Post-Doctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.
Jane is passionate about the development of the UK biotechnology sector and was elected Chair of the Board of Directors of the BioIndustry Association in 2015. She is also a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise. She has presented at a number of parliamentary Select Committees and has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel. In 2016 she was recognised in the PharmaVoice 100, and also in Fierce Pharma’s “Fierce Women in Biopharma” – one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.

Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming currently manages over USD 4.3 billion in assets and investment in over 300 companies.
Nisa was named Top 3 Best Female Venture Capitalist by Forbes in 2018 and Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, CanSino Biotechnology, New Horizon Bio and Berry Oncology. Her other investments include Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), LIH Rehabilitation, Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Sino Biological, Cure Genetics and Jacobio among others.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, member of Committee on Hong Kong Innovation and Technology Development and Re-Industrialization, advisor of Our Hong Kong Foundation, founder of Venture Investors Alliance of Hong Kong and council member of HKUST Business School. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.

Dr. Ruyi He was the Chief Scientist at the Center for Drug Evaluation, the Chinese Food and Drug Administration (CFDA) and fully participated the reform of Chinese drug review system. Dr. He joined CFDA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years.
Dr. Ruyi He joined the CDER at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products. He chaired several working groups that were tasked with drafting and finalizing guidelines for industry, and was also involved in FDA guidance development in multiple therapeutic areas. He was responsible for approving numerous IND and NDA applications. Dr. Ruyi He has received many awards since he joined the FDA, including the FDA Excellence in Review Science Award, CDER Leadership Excellence Award, FDA Award of Merit, and the Department of Health and Human Services Secretary’s Award for Distinguished Service. Dr. He recently joined State Development and Investment Corporation （SDIC）as the Chief Medical Officer.
Dr. Ruyi He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. He is a licensed, board-certified physician in Internal Medicine in the United States of America.

John V. Oyler is the Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, commercial-stage, research-based biotechnology company. Prior to founding BeiGene, Mr. Oyler served as President and Chief Executive Officer of BioDuro, a drug discovery outsourcing company in Beijing, which was acquired by Pharmaceutical Product Development Inc. with attractive returns in 2010. Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology, with funding from Otsuka. Mr. Oyler was previously Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. He has also served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company that grew to $1.7 billion in revenues. Mr. Oyler began his career as a management consultant at McKinsey & Company. He received his B.S. from the Massachusetts Institute of Technology and an MBA from Stanford University.

Dr. Wang Gang is Vice President for Quality (Shanghai) and Global Regulatory Affairs of WuXi Biologics (WuXi). Prior to joining WuXi, Dr. Wang was Chief Scientist at Center for Drug Evaluation (CDE), CFDA. Before that, Dr. Wang spent 12 years at the US FDA. His roles included Senior Policy Advisor in the Office of Manufacturing Quality, Office of Compliance, Center for Drug Evaluation and Research (CDER); Assistant Country Director at FDA's China Office in the US Embassy in Beijing; Expert Biologist, Senior Reviewer and Lead Inspector in the Division of Manufacturing and Product Quality, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER). Dr. Wang is a peer-reviewed expert on CGMP and manufacturing of biologics, with particular expertise in cellular and gene therapy products.
Dr. Wang received his B.S. in biochemistry from Nanjing University and Ph.D. in pharmacology and toxicology from Dartmouth Medical School. He conducted his postdoctoral training in cancer immunotherapy in Dr. Steve Rosenberg’s lab at the National Cancer Institute (NCI), National Institutes of Health (NIH). He was Assistant Professor and Principal Investigator at the University of Texas M.D. Anderson Cancer Center prior to joining the US FDA.

Dr. Anderson is Executive Director of The George Institute for Global Health in China, Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia, and Professor of Neurology and Epidemiology at the University of New South Wales, in Sydney, Australia.
He manages 50 staff in China and leads a global program of large-scale randomised clinical trials and population research with a goal of generating reliable evidence to inform health care providers and policy makers in their decisions regarding optimal strategies for prevention and treatment of cardiovascular disease. His research links clinical medicine and public health, involves multidisciplinary teams in over 15 countries, and uses digital solutions for efficient data capture, analytics and disease management strategies. He has received several awards in recognition of his contribution to research with high health impact.

Zhengqing is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of Merck’s R&D Center in Beijing. As the China R&D head, Zhengqing leads a development team whose primary mission is to bring innovative medicines and vaccines effectively and efficiently to meet unmet medical needs of Chinese patients. In addition, Zhengqing plays the leadership role in building Merck’s global capabilities in China in the areas of quantitative sciences such as data management, biostatistics and epidemiology, and in establishing external collaborations with research institutes, professional societies and industry partners. Under his leadership over the past 7 years, the MSD China R&D Center has been growing dramatically with more than 600 scientists with expertise across clinical research, regulatory affairs, clinical trial operations, pharmacovigilance, project management, biostatistics, epidemiology, and data management.
Prior to joining MSD, Zhengqing took a number of leadership roles with Bristol-Myers Squibb (BMS) including the Head of Clinical Research, China R&D and Executive Director and Head of Oncology & Neuroscience, Global Biometric Sciences. Prior to joining BMS, Zhengqing also worked with Pfizer and Procter & Gamble Pharmaceutics with increasing responsibility in drug development.
Zhengqing has authored and co-authored more than 40 scientific and clinical trial methodology papers and abstracts. He has played leadership role in the development and approval of more than 10 drugs in China and United States.
Zhengqing was born and grew up in China. He received his undergraduate education at University of Science and Technology of China and his PhD degree from University of Wisconsin-Madison with major in Biostatistics. Upon completion of his PhD, Zhengqing took a faculty position in the School of Public Health at State University of New York at Albany.

The National Institute for Health Research Clinical Research Network is the research delivery arm of the NHS. It invests some £300m each year into an infrastructure of clinical research professionals across England, to support rapid study set-up and patient recruitment into clinical research studies (academic and commercial). The Network has demonstrated year-on-year improvements in patient recruitment numbers and delivery times for commercial studies.
In 2017/18 the NIHR CRN supported the recruitment of over 725,000 participants into clinical research studies, 50,112 of these were patients recruited into commercial contract clinical trials.
As the Business Development & Marketing Director at the Clinical Research Network Coordinating Centre since 2014 Matt brings a wealth of experience to the post, having been part of the Network structure for a decade. Matt an Executive Director of the National Coordinating Centre.
In a previous roles he was a member of the leadership team of the National Cancer Research Network and before that worked in the Clinical Research Group of AstraZeneca UK for a number of years.

Dr Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Dr Firth founded ASLAN in 2010 after a career in global pharmaceutical firms and healthcare investment banking. ASLAN is the first Singaporean publicly listed biotech and is currently trading on NASDAQ and the Taipei Exchange.
Previously, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, Carl worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China.
Carl was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline.
Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University. Carl is a member of Singapore’s Health and Biomedical Sciences International Advisory Council. Carl is also an Independent Director of Singapore’s Exploit Technologies and is an Adjunct Professor at Duke-NUS Medical School.

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with two commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Led by Dr. Wu, Ganovo® (Danoprevir), Ascletis’ first direct-acting antiviral agent (DAA) for hepatitis C, was successfully launched in June 2018 and is now commercialized by Ascletis’ 180+ member commercial team. Dr. Wu and his team filed NDA in August 2018 for Ravidasvir, Ascletis’ second DAA for hepatitis C with best-in-class characteristics. Under his leadership, Ascletis has built an innovative R&D pipeline focusing on viral, cancer and fatty liver diseases and consisting of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages.
Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.

Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company focused on oncology and rare disease. He holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He is deputy director general of China Alliance for Rare Disease (CARD), a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.

Dr. Zhavoronkov is the CEO of Insilico Medicine, a leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generation of the novel molecular structures with the desired properties and set up R&D centers in the UK, Russia, Hong Kong and Taiwan. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation. Since 2012 he published over 120 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. Eric completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Guy Spigelman is VP of Portfolio Success at aMoon, a Global HealthTech and LifeSciences VC based in Israel with over $800M under management. Previously, Guy served as CEO of PresenTense – a network of start-up accelerators that launches over 100 startups per years. In this role, Guy founded 7 new accelerator programs, including A3i – the first accelerator in the world focused on Assistive and Aging Technologies.
Prior to PresenTense, Guy served as EVP of Business Development at AposTherapy, an aMoon portfolio company, where he was responsible for the establishment and management of subsidiaries in Europe and APAC. Before this role, Guy held various executive sales, marketing, busines development and product positions at Israeli software companies, including XMPie that was acquired by Xerox and the NASDAQ listed Radview.
Guy serves as a Major (reserves) in the IDF Spokesperson Unit, and was the Chairperson of Merchavim – an NGO promoting shared society at over 500 schools and kindergartens across Israel. Guy lives in Tel Aviv with Naomi and their three daughters, Eden, Galia and Neta.

Dr. Bahl has 25 years of international Pharmaceutical experience working to deliver innovation via drug development projects in the US, Japan, and Europe. His previous roles were with Eli Lilly (2011-2015 as Vice President of External Innovation and Venture partnering), AstraZeneca (1994-2011 Vice President Head of R&D New Opportunities) and Glaxo (1990-1994 Research Scientist).
Dr. Bahl did his first degree in Pharmacy at Kings College London, trained as a pharmacist at John Radcliffe Hospital Oxford and then a PhD in Immunopharmacology at University College London (UCL). Dr. Bahl has delivered over 10 compounds into clinical development from his leadership of drug discovery projects. In his role as Vice President Head of R&D within New Opportunities at AstraZeneca (2007-2011) he ran and initiated R&D collaborations with Alcon in Ophthalmology, Galderma in dermatology and a pioneering collaboration with the Medical Research Council in drug repositioning. In his role within Eli Lilly he helped to pioneer the NIH/NCATs new therapeutic indications pilot and developed Lilly’s R&D input into venture funding. In collaboration with the Chorus Unit at Lilly and Lilly’s Venture funds in the UK, USA and Europe Dr. Bahl was instrumental in the creation of several new companies during his time at Lilly. Some of these companies pioneered new therapeutic areas for Eli Lilly e.g Hearing loss disorders and Immuno oncology.

Dr. Binghe Xu is Professor and Director of the Department of Medical Oncology at the National Cancer Center (NCC) / Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), and Peking Union Medical College (PUMC) in Beijing, China. Director of National Cancer Drug Clinical Research Center. He received his Doctorate of Philosophy and Master of Science degree in oncology from the Peking Union Medical College, and his Doctorate of Medicine from Wuhan University Medical College, China.
His major interests are in basic and clinical research of solid tumors, especially breast cancer, as well as clinical trials of new anticancer agents. He has participated more than 60 clinical trials as PI. Currently, he is leading PI of several regional and global multicenter clinical trials and executive steering committee (EC) as well as steering committee (SC) members of several global clinical trials.
Dr. Xu has published 310 papers in peer reviewed oncology journals, including “Lancet Oncology”, “Annals of Oncology”, “Journal of Clinical Oncology”, “Clinical Cancer Research”, mainly with respect to breast diseases and clinical trials of anticancer agents.
Dr. Xu is the members of several current society, including: Seventh Chairman, Chinese Breast Cancer Society (CBCS)；Chairman designate, Chinese Society of Anti-Cancer Drug Clinical Trial；Chairman, Beijing Breast Disease Society; Standing director, Chinese Society of Clinical Oncology；Member of American Society of Clinical Oncology (ASCO). He is also the panel members of the St. Gallen International Consensus on the Primary Therapy of Early Breast Cancer (2015, 2017, 2019) and ESO-ESMO 2nd (2013), 3rd (2015), 4th (2017) and 5th (2019) International Consensus Guidelines for Advanced Breast Cancer. Dr. Xu has served on the editorial boards of 20 journals including The International Journal of Biological Markers, Chinese Journal of Cancer Research. He is the associate editor of Translational Cancer Research and Chinese Journal of Breast Disease.

Karen Reeves, MD is President and Chief Medical Officer at AZTherapies, a start-up company using a multi-action approach to treat Alzheimer’s Disease and neuroinflammation with Harvard-based science. AZTherapies is currently conducting a global clinical trial in AD. Prior to joining AZTherapies in 2017, Dr. Reeves served at Pfizer under numerous leadership positions including VP Global Head of Clinical Submissions Quality and Innovation and VP Neuroscience Global Research and Development. Dr. Reeves also served as VP, Global Head of Medical Science at Astellas and represented Astellas in Brussels at EFPIA’s Scientific, Regulatory, and Manufacturing Committee.
Dr. Reeves is a senior biopharmaceutical R&D executive with 25 years of scientific, clinical, operational, regulatory, and commercial experience and proven leadership in successful global drug development. She has led Phase 1 - 4 drug development, filed numerous NDAs, and held management positions in business development and strategic partnerships. Dr. Reeves has provided leadership across multiple therapeutic areas including neuroscience, oncology, immunology, infectious diseases, cardiovascular, and urology. Under her leadership, three Pfizer drugs in neuroscience were developed and approved including Geodon/Zeldox for schizophrenia, Geodon IM/Zeldox IM for agitation and Chantix/Champix for smoking cessation. She has a proven track record of innovation in drug development, filing drugs ahead of schedule, decreasing timelines and cost, and mentoring teams. Under her worldwide team leadership, Chantix was filed and approved a year ahead of schedule, was granted FDA Priority Review, gained reimbursement in major markets, and made $800 million in its first year due to this acceleration. Chantix won the Prix Galien Award in 2007 for Best Pharmaceutical, considered the Nobel Prize in industry, and has been prescribed more than 24 million times. Dr. Reeves earned her BA from Yale University and MD from University of Vermont Medical School.

1994年毕业于北京大学化学系，1999年获得美国哥伦比亚大学博士学位（导师：Clark Still教授），2002年在斯坦福大学完成博士后研究（导师：Barry Trost教授）。随后在多个美国生物医药公司从事创新药物研发工作。2009年回国后，在北京大学深圳研究生院任课题组长，2013年获得药明康德生命化学研究奖学者奖。从事药物化学和化学生物学研究；致力于发展共价药物理论和技术体系，并运用于抗肿瘤和免疫功能调控的创新药物研究；化合物伊布替尼（商品名“亿珂”）的主要发明者之一。在J Med Chem、Angew Chieme、PNAS等国际学术刊物和著作中发表论文和章节二十余篇，获得美国、欧盟、中国等授权专利十余项。

Dr. Botti has been Metabomed's CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, which he joined in 2011. During his tenure at Merck Ventures, Dr. Botti set up the Israel Bioincubator Fund and established a number of early stage companies. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel's leading Life Science incubators. Prior to that, he was Senior Director of Business Development at Cogenics. He also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Dr. Botti holds a PhD in Chemistry from the Weizmann Institute of Science where he received the "Dov Elad" prize in Structural Biology and was NIH_ADDP Fellow at Northwestern University Medical School in Chicago.

Dr. Sofie Qiao is the founding president and CEO of Vivace Therapeutics. Prior to co-founding Vivace, she served as managing director of WuXi ventures, the corporate venture arm of WuXi AppTec. Dr. Qiao co-founded the chemistry-driven drug discovery company LEAD Therapeutics in 2006, assembled the management team and played a central role in raising $17 million in Series A financing. The company was acquired in 2010 by BioMarin for up to $97 million, primarily for its PARP inhibitor (Talazoparib), then in preclinical development, which has since been approved by the FDA. Dr. Qiao began her industry career at Genzyme as a medicinal chemist, and later moved into business roles with McKinsey & Company, Syrrx (now Takeda California) and Discovery Partners International (now Galapagos). She received her PhD in organic chemistry from Massachusetts Institute of Technology and A.B. in chemistry from Harvard University.

Darren is co-founder and CEO of Elpiscience Biopharmaceuticals。 He is also a Venture Partner of Lilly Asia Ventures (LAV)., Inc. Prior to that Darren was Global Vice President of Roche Partnering for Asia and Emerging Markets, as well as a leadership team member of Roche Partnering, Roche’s deal-making body that manages the company’s business development across the board including licensing and M&A. In this role Darren was responsible for driving the strategy and execution of partnering activities in the territory of Asia and Emerging Markets encompassing over 100 countries. During his tenure Darren championed and oversaw the closing of many key transactions between Roche and partners worldwide. He managed a global team and established a strong business network in key countries like China, Japan, Korea, Australia/New Zealand, Russia and Brazil.
A repeat entrepreneur himself, Darren spent a long career at the Procter & Gamble Company with increasing responsibilities in drug R&D and business development. He co-founded and managed as CEO of PharmaLegacy Laboratories in Shanghai in 2008, which became a premium CRO providing high-quality drug discovery services to a global clientele until today. Darren has been a highly respected leader in global life sciences and a sought-after speaker in various business forums. He was also an avid community builder exemplified by completing one of the longest services as a board member of the BayHelix Group.
Darren got his medical training at China Medical University, a PhD from University of Sheffield at UK, and a MBA from University of Chicago.

Yanni Lin is the Chief Technology Officer and co-founder of Cure Genetics Co., Ltd. She is passionate about using genome engineering to create clinical and manufacturing solutions in advanced therapies and diagnostics. Yanni has 9+ years of experiences in genetic engineering of mammalian systems using TALENs and CRISPR/Cas9 systems for translational research. She is currently in charge of projects about developing better cell and gene therapy products for regional and global unmet medical needs.
Prior to co-founding Cure Genetics in 2016, Yanni worked at Synthetic Genomics Inc., where she engineered the pig genome to facilitate xenotransplantation. Yanni earned her PhD degree in Biomedical Engineering at Georgia Institute of Technology and Emory University. Her PhD research focused on optimizing and analyzing gene-editing tools and applying them in various therapeutic settings such as Sickle Cell Anemia, HIV, and cancer immunotherapy.

Misti Ushio is the CEO of TARA Biosystems.
TARA Biosystems develops physiologically relevant 3D tissue models for drug discovery and development applications. The company’s Biowire™ II platform enables generation of large amounts of human relevant data for predictive drug development. TARA accelerates discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities, and also evaluates early cardiac risk assessment of drug discovery candidates.
Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she advised and invested in life science companies to help them translate their transformational science into commercially successful companies.
Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies. In 2018, she was named to Fast Company’s Top 100 Most Creative people in Business.

Naheed Kurji is the President and CEO of Cyclica, a Toronto-based, venture-backed biotechnology company that has recently been named by Deep Knowledge Analytics as one of the top 20 AI in Pharma companies globally. At Cyclica, Naheed and his team are reshaping drug discovery by offering the pharmaceutical industry an integrated computational biophysics and AI-augmented platform that enhances how scientists design the best drugs for patients, not just for a single protein. Naheed focuses on strategy and corporate development activities to affect change in the pharmaceutical industry with a vision of reducing drug discovery cycle times and risk with a holistic in silico polypharmacology and structural pharmacogenomics first strategy. In his role at Cyclica, Naheed is a co-founder of The Alliance for Artificial Intelligence in Healthcare (AAIH), of which Naheed is 1 of 4 appointed Executive Officers. He is passionate about how people interact with technology to make more informed and faster decisions, and is dedicated to advance the responsible application of AI to healthcare problems. He is an experienced professional specialized in strategic planning, corporate finance and entrepreneurship, and has been featured in the Globe and Mail, CBC, Forbes, Vanity Fair, StartUp Health Magazine, WuXi Insider Perspective, and VentureBeat. Naheed is also a guest lecturer at various universities and is a graduate of the University of Toronto, Rotman School of Management where he obtained his MBA.

Willliam Robert Keller joined Roche in Basel 1972 and served from 1974 to 2003 in several marketing and General Manager positions at Roche Group in South America and Asia. From 1994 to 2003 he oversaw and established Roche in China as General Manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. In 2003, he founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry strategies for foreign biotech companies into the China market. He has been Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment (SAEFI) and Deputy General Manager of Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd.
He is currently Chairman of Coland Pharmaceuticals Ltd. a listed company on Taiwan Stock Exchange and holds directorship as independent director at Wuxi Biologics Ltd. and Hua Medicine, both listed at HK Stock Exchange and Cathay Industrial Biotech Ltd.. Previously, he served as an independent director at Alexion Pharmaceuticals Inc, China Nuokang Bio Pharmaceutical Inc. and Fosun Pharmaceutical Co. Ltd. He also was a supervisor and Board member of TaiGen Biotechnology Co. Ltd. and as Chairman of HBM Biomed China Partners.
Mr. Keller is Honorary Citizen of Shanghai.

Dr. Li Chen, Chairman, Founder, Chief Executive Officer, and Chief Scientific Officer. leads Hua Medicine a clinical stage biotech company whose mission is to bring personalized diabetes medicines to patients in China and worldwide. He is a pioneer in collaborative innovation in China and advanced Hua Medicine with an operation principle of high standards, high quality and create high value. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Under his leadership, Hua Medicine completed successfully a POC study and initiated China NDA enabling process. During this period, Hua Medicine raised 200M USD and established the leading position of Hua Medicine in China biotech industry.
Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 35 granted patents and an author with over 60 publications.

Dr. Chris Chen is currently Chief Executive Officer at WuXi Biologics, a Hong Kong listed public company with market cap of approx $10+ billion USD. At WuXi he has built a world-class open-access integrated biologics discovery, development and manufacturing platform enabling full spectrum of companies ranging from 2-employee virtual companies to Top 20 global large pharma. Under his leadership, WuXi has assembled one of the largest biologics teams with over 2700 scientists enabling 60+ biologics entering into clinical trials per year. WuXi has also pioneered disposable-bioreactor based state-of-the-art commercial manufacturing facility and built the first 30,000L bioreactor capacity in the world using disposables. The globally leading platform developed by WuXi Biologics is now serving more than 200 companies worldwide.
Dr. Chen obtained his dual bachelor degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in biologics development, manufacturing and quality in the US, where his previous assignments include director and manager positions at Lilly and Merck. Dr. Chen later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar etanercept, and obtained regulatory approval for the program in China in 2011. He chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at multiple conferences. He is also adjunct professor at Shanghai Jiaotong University. Dr Chen is co-author and co-inventor of 60+ publications and patents.

Ray is a seasoned executive, bringing his unique perspective as a clinician-scientist leading and growing start-up companies. He joins Twist Bioscience from Aravive Biologics (now Aravive, Inc.) where he was a Founder and the Executive Chairman of the Board. He remains a non-executive Director. Concurrently, he ran 526 Ventures, a strategic consulting company working with multiple public and private biopharmaceutical companies. Previously, he served as a venture partner at Bay City Capital LLC. Prior to his time at Bay City Capital, he held a number of executive positions in biotechnology companies including Chief Scientific Officer of Aviir and Vice President of Translational Research for VIA Pharmaceuticals. Before moving to industry, Ray was a practicing cardiologist and an Adjunct Clinical Instructor of Medicine at Stanford University. He received his MD from Harvard Medical School and trained as an internist and cardiologist at Stanford University, while also receiving finance education at Stanford Business School. He has received numerous honors and research awards, has authored several peer reviewed papers, and is an inventor on multiple patents.

Dan Wang, MD, is the Head of Johnson & Johnson Innovation, Asia Pacific. In this role, she is responsible for managing a portfolio of co-investments spanning across all three sectors of Johnson & Johnson and expanding the external networks within the innovation ecosystem.
Dan has over 20 years of experience in the life sciences sector. Prior to joining Johnson & Johnson Innovation, Dan has worked with Becton Dickinson(BD), e-Capital Corporation, Express Scripts and Johnson & Johnson by leading the local and global Research & Development, Medical Affairs and clinical research teams. She also has strong track records in strategic innovation of identifying new product opportunities and external partnerships.
Dan holds MD and MSc degrees from Peking University and she received her MBA from Goizueta Business School, and MPH from Rollins school of Public Health, Emory University, Atlanta in the U.S.

Dr. Curtis Keith has served as Chief Scientific Officer of Harvard University’s Blavatnik Biomedical Accelerator (previously, Harvard Biomedical Accelerator Fund) since 2008. By providing financial and other support, the Accelerator helps bridge the gap between early-stage research emanating from Harvard labs and validated de-risked technologies that are ready for industry partnership.
To date, the Accelerator has provided over $20 million in direct funding to 109 projects from across Harvard University. Nearly half of completed Accelerator projects have been partnered with industry – either through startup formation, or collaborations and licensing agreements with existing biotech and pharmaceutical companies. These partnerships have returned more than $60 million to Harvard and its researchers, and startups based on Accelerator technologies have succeeded in raising more than $500 million in equity financing.
Prior to joining Harvard University, Dr. Keith was Senior Vice President of Research at CombinatoRx, a Massachusetts-based biotechnology company he cofounded in 2000. Under his leadership, CombinatoRx created an integrated technology platform for the discovery of multi-target therapeutics, yielding a broad pipeline of preclinical and clinical drug candidates in areas including rheumatoid arthritis, psoriasis and neurodegenerative disease. Dr. Keith earned his BSc in biochemistry from McGill University and received his AM and PhD in chemistry and chemical biology from Harvard University.

Robert S. Sullivan joined the Rady School of Management at UC San Diego as its founding dean in January 2003. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management.
Dr. Sullivan has successfully recruited top-tier faculty, from universities such as the University of Chicago, MIT, New York University, Northwestern, Princeton, Stanford, the Wharton School and Yale. Under Dr. Sullivan’s leadership, the Beyster Institute was integrated with the Rady School, thereby increasing the school’s brand in San Diego and throughout the world. In 2013-14, Dr. Sullivan served as chair of the Association to Advance Collegiate Schools of Business (AACSB International), the premier accrediting body for business education. During Dr. Sullivan’s tenure, the Rady School opened and moved to Otterson Hall in June 2007, followed by Wells Fargo Hall in May 2012. In 2004, Dr. Sullivan secured the naming gift for the School, $30 million from the Rady Family Foundation. In 2015, Dr. Sullivan secured an additional $100 million investment to endow the Rady School.
Prior to joining UC San Diego, Dr. Sullivan was dean of the Kenan-Flagler Business School of The University of North Carolina, Chapel Hill, and dean of the Graduate School of Industrial Administration at Carnegie Mellon University.
Dr. Sullivan holds a doctorate in operations management from Pennsylvania State University, a master’s degree in production management and quantitative methods from Cornell University and a bachelor’s degree in mathematics from Boston College.

Dr. Jonathan Wang is a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm, where he founded OrbiMed Asia. He is a HKEX Biotech Advisory Panel member and is a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders. Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University. He has close to 30 years of healthcare and life sciences experience, spanning investment, entrepreneurship, finance and research. He has been named one of the top 10 healthcare investors in China (ChinaVenture) and has invested in many successful companies, such as ZAI Lab, Genewiz, Apollomics, ForteBIO and EA. He serves as the Chairman of Apollomics Pharmaceuticals.

Toshio Fujimoto, MD, MBA, is the General Manager of Shonan Health Innovation Park (iPark), a science park launched by Takeda Pharmaceutical Company Ltd in Shonan, Japan in April 2018. In his current role, Dr. Fujimoto provides strategic leadership and oversight for all key iPark activities, including development and execution of business and financial plans, coordination of site operations and services, tenant recruitment and management, and marketing and public relations activities. He implements the iPark's vision to be an open innovation ecosystem which builds meaningful collaborations with academia, biotech, pharma companies, and the government.
Prior to joining Shonan iPark, Dr. Fujimoto held positions with increasing responsibility at Eli Lilly Japan. Most recently he was Vice President of the Medicine Development Unit, where he oversaw the R&D Management function in Japan.
Earlier in his career, he completed a clinical fellowship in General Thoracic Surgery at the Mayo Clinic in the U.S, worked as an Assistant Surgeon at Ruhrlandklink in Essen and Freiburg University Hospital in Germany.
Dr. Fujimoto received his M.D. from Kyoto University and his M.B.A. from Kobe University. He completed his residency at the Department of Thoracic Survey at Kyoto University Hospital and affiliated local hospitals.

Sophie Sun is currently Managing Director of Merck China Innovation Hub and Vice President of Merck Strategy and Transformation China. In this role, she leads the corporate efforts of driving strategic planning and initiatives of innovation and digitalization for Merck in China. Sophie is a member of the global leadership team of Group Strategy & Transformation, and a member of China Country Council for Merck. She is also the Chair of China Digital Council for Merck.
Sophie joined Merck in 2009, and took different roles with increased responsibilities in the field of communications, sales, marketing, strategy and business development. Sophie worked in both strategic markets including China and US, and global function of GBF Oncology. She was a member of the China Senior Leadership Team of Merck Biopharma China before moving to the US in 2013, where she worked on the global launch of Merck’s first immuno-oncology drug, as Director Global Commercial Oncology among other roles.
Before joining Merck, Sophie worked as a consultant for over eight years in China and France, and served a broad portfolio of clients from different industries, including healthcare, technology, chemicals and finance with international marketing and communications groups, including IPG and WPP.
Sophie holds a MBA degree from MIT Sloan School of Management and a MA degree from Renmin University of China. Sophie translated and published two books in the psychology management area. She is a board member for MIT Alumni Club of Shanghai, and a member of Bayhelix Group. She is an active speaker on innovation, digitalization and female leadership, and mentor and jury member for several startup incubators, accelerators and other organizations or programs.

Ken is chairman and chief executive officer of Goldman Sachs in Asia Pacific
Ex-Japan. He is a member of the firm’s Management Committee and co-chairs the Asia Pacific Management Committee.
Previously, Ken served as president of Goldman Sachs in Asia Pacific Ex-Japan from 2013 until 2017. Prior to relocating to Hong Kong, he was global head of the Healthcare Banking Group and global co- head of the Technology, Media and Telecom Group. Ken joined the Healthcare Banking Group as a founding member in 1995 and became head of the global medical device banking practice in 1998 and head of the global pharmaceutical banking practice in 2001. He began his career with the firm as a summer associate in 1991 and joined the Corporate Finance Department in 1992. Ken was named managing director in 2000 and partner in 2002.
Prior to joining the firm, Ken was a lieutenant commander and naval aviator in the US Navy.
Ken is an adjunct professor at Columbia Business School and a member of the BioFrontiers Institute Advisory Board at the University of Colorado. He also serves on the International Advisory Council of the Faculty of Business and Economics at The University of Hong Kong, and the Asia Pacific Council of The Nature Conservancy.
Ken earned a BA from the University of Colorado and an MBA as a merit fellow from Columbia University.

Mr. Wu joined Temasek in October 2013 and is currently Joint Head, Enterprise Development Group and Head, China.
Mr. Wu was previously President of CITIC Private Equity Funds Management, a position he held since December 2009. He concurrently served as Chairman and CEO of Goldstone Investment Co. Ltd., the direct investment arm of CITIC Securities.
Mr. Wu began his career with McKinsey, rising to become Senior Partner and Head of Asia Pacific M&A Practice. He was also General Manager of McKinsey Beijing, where he was responsible for providing M&A, corporate restructuring and IPO advisory for large Chinese enterprises. He had advised a number of leading Asian companies in their international expansion effort. He subsequently joined the Lenovo Group, and led the acquisition and integration of the IBM PC business, serving as Chief Strategy Officer, Chief Integration Officer, Chief Transformation Officer/ Chief Information Officer of Lenovo Group.
Mr. Wu was later appointed to Lenovo parent Legend Holdings, as Executive Vice President responsible for the overall business operations and overseeing its direct investment business.
Mr. Wu serves on the board of China Social Entrepreneur Foundation.
Mr. Wu holds a PhD in Biochemistry from Harvard University and a BSc. in Molecular Biology from University of Science and Technology of China.

Andy Lin is an experienced entrepreneur, accomplished investor and dedicated philanthropist in China.
Mr. Andy Lin founded Loyal Valley Capital (“LVC”) in 2015. LVC differentiate itself by in-depth research and extensive proprietary deal sources in china. Since establishment, LVC has invested in such phenomenal enterprises as Bilibili, #1 online platform for China’s generation Z, Toutiao, #1 AI-powered news aggregator in the world, Luogic Thinking, #1 online educational podcasts platform in China, Happy Twist, #1 Creative theatre company in China , Junshi Bioscience, #1 PD-1 biotech company in China and Kanghua Hospital, #1 private hospital in China.
Prior to establishing LVC, Mr. Lin was the founder and CEO of China Universal Asset Management, one of China’s leading investment firms with US$70 billion AUM by the time he left in 2015. Under Andy’s 11 years of stewardship, CUAM has grown from the 47th licensed asset management company to the largest equity investor in China, ranking consistently #1 among hundreds of peers in terms of performance in active equity funds, generating 28.4% of gross IRR over 11 years for its flagship fund.
Aside from his career aspirations, Mr. Lin established the CUAM and LVC Foundations, which have donated 12 elementary schools to assist more than 3000 children for schooling in poor and remote regions. Mr. Lin received his MBA from the Harvard Business School and he also holds a MA and BA from Fudan University.

Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1400 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a prior board member of BayHelix Group. Greg is considered a leading expert on China’s life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland.

Mr. Lee Ligang Zhang has been a successful serial entrepreneur and business executive since he dropped out from graduate school at Harvard University in 1998, bringing his knowledge and acumen to a number of companies in his professional career that range from healthcare to the Internet, and has built two companies which went public on NASDAQ.
Mr. Zhang founded iKang Healthcare Group, Inc. (“iKang”), successfully merging healthcare delivery system with a versatile online platform to build a preventative healthcare service network that spanned the entire country. This “anytime, anywhere” network was to become the blueprint for the industry that transformed how individuals accessed healthcare services in China.
Since its inception, Mr. Zhang has been serving as iKang’s Chairman and Chief Executive Officer. iKang was listed on the NASDAQ in April 2014 and is a leader in China's fast growing middle to high end private preventive healthcare services market.
Prior to iKang, Mr. Zhang was a co-founder of eLong.com and served as CEO from 1999 to 2003. eLong.com was then the second largest online travel service company and listed on the NASDAQ in October 2004. From 1998 to 1999, Mr. Zhang served as head of product development at Sohu.com, a leading NASDAQ-listed Chinese Internet portal. Mr. Zhang founded the journal Harvard China Review in 1997 and co-founded the Harvard China Forum in 1998 while studying at Harvard University.
Mr. Zhang is currently also a board member of MSH HK Limited, which operates the largest high end private health insurance service platform in China. Mr. Zhang serves as Vice President of Chinese Physicians Group Association with Chinese Non-government Medical Institute Association, Vice President of Beijing Health Management Association, and Vice President of the Harvard Club of Beijing as well Vice President of Shanghai Alumni Association at Fudan University. Mr. Zhang was named as EY Entrepreneur Of The Year 2014 National Life Sciences Award Winner in China.
Mr. Zhang studied biology as an undergraduate student at Fudan University in China, and went on to receive a bachelor's degree in biology and chemistry from Concordia College in the US before obtaining a master's degree in genetics from Harvard Medical School Division of Medical Sciences.

Prof. Cai is the Director of Center for Healthcare Management and Policy and Adjunct Professor of Economics at China Europe International Business School (CEIBS). He has been involved in teaching, research and consulting work at universities, consulting firms and government in the area of healthcare nearly thirty years in both U.S. and China. He has published extensively in the areas of health economics and health policy. He participated in the design, implement and evaluation of the first comprehensive health care reform plan (Massachusetts) in the U.S. and was also actively involved in design of the new health care reform plan in China.
Prof. Cai was the cofounder of the Institute of Economic Development and Business School at the East China University of Science and Technology (Shanghai) and the first Chair of Department of Public Economics at Fudan University. He received 1990 Sun Yie-fang National Economic Science Prizes-Best Paper Award, 2002 Most Outstanding Abstract Award by AcademyHealth in the US, and 2009 Excellent Paper Award from Shanghai Social Science Annual Conference. He received Ph.D. in Public Policy from the Heller School for Social Policy and Management at Brandeis University in 1997 (US), his MA in Economics at Fudan University in 1984 and his BA in Economics at East China Normal University in 1982.

Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He currently manages over US$ 4.5 billion with 5 US$ funds and 5 RMB funds. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer. The portfolio companies that Feng invested and manages include APUS, ThunderSoft, Macrosan, Meituan, Baihe, LineKong, ChineseAll, GigaDevice, BGI, China Music, LianLian, Burning Rock Biotech, Hillstone Networks, Spreadtrum, CITIC Pharma, Aerohive Networks, etc.
Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. Feng is recipient of Ernst & Young Entrepreneur of the Year (2002) and CRN Innovator of the Year (2003) awards. He has extensive technical and managerial experiences in computer, communication and data networking industries.
Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.
Feng serves on the Board of Directors of Tsinghua University Foundation, the Director of Schwarzman College at Tsinghua University, the Distinguished Visiting Professor of Tsinghua University, the Chairman of Asia Advisory Board of the USC Viterbi School of Engineering, the Advisory Board member of Stanford Institute for Economic Policy Research (SIEPR), the member of Asia Council of Wharton School, the Director of Brookings Institution, the member of China Council of Harvard GSAS, the member of China Entrepreneur Club, and the member of Founding Council of Future Forum, etc.

Born in 1971, graduated from Shanghai Jiaotong University with Bachelor’s degree in Electronic Engineering, Shanghai University of Finance and Economics with Master of Chinese Medicine, Chinese Academy of Traditional Chinese Medicine with Doctor of Chinese Medicine, and EMBA of China Europe International Business School (CEIBS). He is the Chairman of Meinian Onehealth (Group) Co., Ltd (SZ 002044), and Chairman of Tianyi Investment Group, Vice President of China Association for Public Companies, and committee member of China National Health Commission health improvement and educational expert commission.
Meinian is the largest professional checkup and medical service group in China and the largest platform for preventive services and primary healthcare all over the world. It was founded in 2004, owning almost 600 examination centers in over 200 core cities. It provided 30 million customers for professional checkup and healthcare service in 2018 and the number is expected to reach over 100 million in 2021. Meinian Onehealth is also one of the top health service companies with highest market value in China.
To be an important complement to the national healthcare system, Meinian Onehealth follows the business logic as professional checkup, precise result, high risk screening, risk assessment, and health service, adheres to its core business strategy as “expanding core business, building ecosystem and completing closedloop” to build a health industry cluster in China. Meinian Onehealth focus on quality improvement and technology innovation to lead its business with its unique development model of volume, technology and ecosystem. Based on precise health data volume, and strong operation and distribution channels, Meinian Onehealth has cultivated a group of high-tech unicorn companies and committed to being health service and life science company with an unlimited potential by quality-driven and data-driven.
As the major investor of Meinian Onehealth and its ecosystem partner companies, Tianyi Group establishes a strong pipeline to empower Meinian’s core competence in long term, especially in the areas of advanced diagnosis, precision screening, AI, health management, and medical insurance, etc.
Together with collaborators, Tianyi Group is building a collaborative, innovative and supportive ecosystem to create win-win situations.

Dr. Bin Li is the founder and Chief Investment Officer of Ally Bridge LB Healthcare Fund and a partner of Ally Bridge Group. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he was recognized as the best Asia/China healthcare analyst for many years consecutively from the two well-known Wall Street investor polls - "Institution Investor" (II) and "Greenwich", including No. 1 Asia Healthcare Analyst by II for seven consecutive years (2008-2014), No.1 China Healthcare Analyst by II for 5 consecutive years (2010-2014), No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock picks in 2010, and No. 1 Asia Healthcare Analyst by other investor surveys such as Greenwich and Asiamoney.
Prior to that, he was the head of Merrill Lynch Greater China Healthcare Research Team. He also was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Before that, he worked at Merck Research Laboratory as a scientist. Dr. Li holds a Ph.D. in biochemistry and MBA from New York University, and a BA from Fudan University.
Since its inception in 2015, Ally Bridge LB Healthcare Fund was nominated every year as one of the best performing hedge funds in Asia by EurekaHedge and AsiaHedge, two well-known public fund industry research institutions.

After completing pre-med at Peking University, Dr. Zhang earned M.D. from Peking Union Medical College. Then, received Ph.D. in Health Policy from Harvard University in 2005. Dr. Zhang joined Wuxi App Tec in 2018 as Chief Strategy Officer and Senior Vice President. In this role, Dr. Zhang is responsible for strategic management to promote the development of new businesses as well as the existing core businesses. Prior to joining WuXi, Dr. Zhang worked as a faculty for Peking University and China Europe International Business School (CEIBS) for a dozen years. He was the founding director of Health Care Management and Policy Center at CEIBS. Dr. Zhang has worked with HBS, LBS, INSEAD and IMD on executive education. Providing service which including but not limited to: J&J, Novartis, Roche, China Merchant Group, and Minsheng Bank. Dr. Zhang has rich strategic consulting and leadership development experience, his expertise focus on business innovation, health care organization innovation, and digital transformation.

Dr. Kai Wang is the Founder and CEO of OrigiMed, a medical science and technology transforming company which devotes to provide comprehensive molecular diagnostic information for cancer patients, molecular pathology and genomics services for partners. Dr. Wang has over 15 years of extensive experience in bioinformatics and precision medicine. Prior to OrigiMed, Dr. Wang worked at Foundation Medicine in US at the early stage. With the combined background of clinical medicine and bioinformatics, he was responsible for bioinformatics pipeline, assay validation, new product development, clinical data analysis, also involved in pharma collaborations, knowledgebase system, report annotation and medical consultation in the 5 years at Foundation Medicine.
Dr. Wang has focused on next generation sequencing analysis since 2007. From 2001 to 2003, Dr. Wang worked on international Sanger sequencing projects at BGI in Beijing. Dr. Wang received bachelor degree in clinical medicine from Jilin University, and Ph.D. in Bioinformatics from Technical University of Denmark and UCLA. He continued his clinical NGS research in cancer at Harvard University. Dr. Wang has published 80+ SCI scientific publications and 150+ conference posters/talks, and developed several bioinformatics software and pipelines that are used global widely.

Guang Ning, M.D., Ph.D., he is Director of Shanghai Institute of Endocrine and Metabolic Diseases, Head of Shanghai Clinical Center for Endocrine and Metabolic Diseases and Director of The Key Laboratory for Endocrine and Metabolic Diseases of Chinese Health Ministry. He is the Chair of Chinese Society for Clinical Endocrinologists, Member of the Executive committee of International Endocrine Society and former president of Chinese Society for Endocrinology. He is the chief Editor of the Journal of Chinese Endocrinology and Metabolism, Co-Chief-Editor of the Journal of Diabetes, member of the Advisory Board for the Endocrine Reviews and Nature Reviews Endocrinology, associated editor for Journal of Endocrinology and Journal of Molecular Endocrinology. His research interests mainly included diabetes, obesity and adrenal diseases. He has published more than 300 papers in peer-reviewed journals, including JAMA, Nature Genetics, Nature Cell Biology and Annals of Internal Medicine.

陆思嘉博士毕业于美国哈佛大学，高通量基因测序专家，MALBAC全基因组扩增技术共同发明人，江苏省“双创计划”引进人才，上海市人大代表，上海市“千人计划”特聘专家。共获得专利30项，在国际著名期刊发表论文29篇，成果多次在国内外学术会议做重要报告。
亿康基因(Yikon Genomics)致力于开发应用单细胞全基因组及转录组扩增和技术测序，在陆思嘉博士的带领下，亿康基因已成功发明并转化多项全球领先技术，并在在生殖遗传、妇幼健康、肿瘤筛查与检验、生命科学研究等领域取得骄人成果。在预防出生缺陷领域，亿康基因将单细胞全基因组测序技术应用于PGS、PGD三代试管婴儿的胚胎染色体检测，并发明NICS无创胚胎染色体筛查技术、MaReCs 等位基因映射识别胚胎平衡易位携带状态技术、ChromInst快速染色体筛查等先进技术，有效阻断遗传病的传递，降低出生缺陷率。在肿瘤筛查诊断领域，亿康基因与多家医院合作开发出快速无创染色体拷贝数检测等技术，提高伴随诊断中的肿瘤检测效率。未来，亿康基因将继续以“解读生命密码，改善生命历程”为使命，为预防出生缺陷、阻断遗传病传递、提高出生人口素质、改善肿瘤病患临床结局提供优质的医学检测服务，为亿万人的健康和新生做出贡献。

发起创办山蓝资本，具有医疗专业基金发起、募资、团队组建、投资、投资后管理等全过程管理经验；
具有整个医疗企业创业全过程成功经验：上海微创医疗器械（集团）有限公司（香港上市公司）11年的创业经验；主管研发、新业务开拓、投资及并购部门，积累了包括技术研发﹑营销﹑供应链﹑品质与临床法规﹑人事与财务﹑战略规划﹑资本运作与IPO等全面管理运营经验；
具有在医疗技术领域深厚的功底：南开大学物理学本科及理学博士、英国牛津大学博士后、深厚的技术研发背景,获国家科技进步二等奖和发明奖，十余项科技项目负责人，获得国家超过一亿元科技经费，获得20多项专利授权；
开发的心脏药物支架总计产生40亿人民币销售额，连续8年位居全国销售份额第一；
主导及参与4项国际国内并购及合资的谈判及交易，总金额3亿美金；
发起创立三家微创医疗集团的子公司，目前三家子公司每年销售超过15亿元；
在4家国家级医疗行业协会任理事，中国医疗器械产业投资与并购CEO峰会创始发起人及连续5届大会主席，具有广泛人脉。

Martien is a Managing Partner at Forbion, a leading European venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people’s lives.
Forbion currently manages over EUR 1 Billion, including its most recent flagship fund, Forbion IV, launched in 2018 with EUR 360 Million in capital commitments. Forbion has a team of seasoned investment professionals with head offices in Amsterdam, the Netherlands, and an office in Munich, Germany. Forbion helps companies to bridge research and development through the team’s expertise in drug development and company building. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 60 companies.
Martien van Osch was a founding Partner at Forbion and has a leading role in the Forbion Team and the Portfolio. Within the Portfolio, he was responsible for the investments in PneumRx (sold to BTG in 2015), Circulite (sold to Heartware in 2013), Pathway Medical (sold to Bayer Medrad in 2011), Impella (sold to Abiomed in 2005), Flowmedica (sold to Angiodynamics in 2009), Santaris (sold to Roche in 2014) and Acadia (IPO on Nasdaq in 2004). He currently serves on the boards of Mitralign , Autonomic Technologies and Staten Biotechnology.
He recently moved with his family to Singapore from where he will lead Forbion’s activities into Asia.

Dr. Jason Liu is a seasoned executive with nearly 30 years of experience in life science industry, including 20 years of senior leadership in multinational clinical diagnostics and medical device companies. Dr. Liu has extensive experience in cross-culture business integration, merger & acquisition, new business development, and operation. Dr. Liu joined WuXi AppTec Group in 2014 as Senior Vice President and Division Chief Operation Officer. He established the Lab Testing Division (LTD) through integrated testing platforms in China and US, rapidly expanded its global operation, and enhanced LTD’s leading position in pharmaceutical and medical device testing sector. In January 2018, Dr. Liu led teams to establish WuXi Diagnostics (WXDX), a joint venture between WuXi AppTec Group and Mayo Clinic. He became the CEO for WuXi Diagnostics on Jan 1st, 2019.
Before joining WuXi AppTec Group, Dr. Liu worked at Hologic-Gen Probe, Life Technologies-Applied Biosystems, and Bio-Rad as regional GM for APAC and China, global business unit GM at US headquarters etc.
Dr. Jason Liu received his Ph.D. in Molecular Biology & Human Genetics from Loma Linda University, MBA from Pepperdine University, and BA in Biochemistry from Shandong University, China.

Worked in product teams of Tencent and Alibaba for xx years and then founded LinkDoc in 2014 as CEO.
Built LinkDoc into the largest and NLP technology enabled oncology real world data platform and then data-enabled solution platform for patients (remote patient management), physicians (AI diagnostics) and pharmacos (R&D acceleration and RWE solution)
LinkDoc is now a company of 1,400 employee and has raised D-round fund with prestigious industry (e.g. CBC, Allybridge etc.) and sovereign fund investors (e.g. CIC)
LinkDoc have gained recognitions from both government and industry: 1) Vice Premier Han, Zheng visited LinkDoc for the effort in technology and healthcare innovation; 2) 2017 World Internet Conference selected LinkDoc as the only start up as "Top 10 Internet technology best practice case example" 3) joined CSCO Intelligent Medicine committee as committee member to promote data enabled AI for oncology diagnosis and treatment
Received undergraduate degree from Beijing University of Posts and Telecommunications with computer science major and EMBA from China Europe International Business School (CEIBS)

Mr. Andy A. Liu is the CEO of CW Data Technologies. (中电药明数据科技)
CW Data is a joint venture between China Electronics Corporation: a state owned enterprise with national responsibilities for the development and management of China’s healthcare data assets and WuXi Apptec: the leading global pharmaceutical and medical device open-access capability and technology platform company with global operations.
CW Data is a healthcare technology company with deep expertise in data collection, data mining and data analytics. The company provides end to end technology solutions and services for stakeholders ranging from pharmaceutical companies, providers, payers, policy makers and healthcare professionals.
Mr. Liu was previously the President of Asia Pacific and China for IQVia. (Previously known as IMS Health) Mr. Liu managed the Data Analytics, Commercial Effectiveness and Consulting businesses for the entire Asia Pacific. Mr. Liu was responsible for managing the P&L of the entire region inclusive of 17 countries including China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Taiwan, Bangladesh, Sri Lanka and Pakistan.
Mr. Liu has spent many years with multinational companies such as Merck and UCB Pharma holding several executive management and leadership positions in the US and Asia. Mr. Liu has also spent many years with private equity firm TPG as an operator running TPG portfolio companies including IMS and Moksha8.
Mr. Liu's area of focus is healthcare big data analytics. He also has extensive experience in product launch and commercialization: inclusive of regulatory approval, pricing, customer acquisition, marketing and sales execution. He has successfully managed and launched products across key therapeutic franchises such as hypertension, atherosclerosis, anticonvulsants, arthritis, antihistamine, osteoporosis and diabetes. He also has strong experience in deal transactions, investments, joint ventures and mergers and acquisitions in the life sciences sector.
He is also currently serving as a Board of Directors for the Hong Kong Government led Applied Science and Technology Research Institute (ASTRI). He is also a Board Member of HKBIO.

Dr. Li currently is Vice President, Digital China Health Technologies Corp Limited. He is also an Adjunct Associate Professor of Cincinnati University, USA and Adjunct Professor of Shanghai Jiao-Tong University China. In the meantime, Dr. Li has been invited as a member of the Expert Advisory Committee, Clinical Research, Evaluation, and Translation Group (CREAT), under China Cochrane Center. Dr. Li is a member of International Society of Pharmacoeconomic and Outcomes Research (ISPOR) Asian Consortium Advisory Committee. And he currently is a member of the Editorial Advisory Committee of Journal of Value in Health, Regional Issues.
Dr. Li has focused on research of health economics and epidemiology across disease areas. He worked for more than 20 years in either the Headquarters or the Asian Regional Office of multinational pharmaceutical companies, including Bayer, GSK, BMS, and AbbVie. From these works, Dr. Li had covered markets of US, Europe, Latin America, and Asia. Dr. Li specialty is health policy evaluations using epidemiology methodology, including health economic evaluations, real world study design/analysis, and implications. Besides speaking at different professional conference, Dr. Li has extensive publications based on his research.
Dr. Li graduated from University of North Carolina at Chapel Hill, USA with a PhD in Health Services Research/Epidemiology and a Master of Public Health in International Health Policy.

Ms. Gao Xinxin is CEO and founding partner of Jiangmen, a venture capital focusing on discovering, accelerating and investing in startups leveraging innovations to create business value. Jiangmen offers three major services: matching with benchmark customers, vertical tech communities, and investment fund. Jiangmen Investment Fund focuses on areas including machine intelligence, IoT, natural human-machine interaction and enterprise computing. Over the past year, Jiangmen Investment Fund has invested in over 10 tech startups with high potential.
Before founding Jiangmen, Gao Xinxin was CEO of Microsoft Accelerator China and incubated 126 innovative tech startups with valuation over RMB38 billion by the end of 2015. Gao Xinxin worked at Microsoft for 16 years and held management positions in sales, marketing, channel management, government cooperation, strategy and investment. Before joining Microsoft Ventures, Gao Xinxin led a sales team with near 100 members to become No.1 in Microsoft globally.
Gao Xinxin received MBA degree and INSEAD EMBA degree from Tsinghua University.

张猛，腾讯医疗副总裁。凭借对医疗行业深厚的热忱和经验，张猛于2016年12月加入腾讯，主要负责数字化医疗创新项目的孵化，目前已成功打造一款全新医学科普类产品，赢得了广大用户、医生和行业的广泛认可。
张猛在医疗行业拥有超过20年经验，由此积累了深刻的行业洞察和对未来数字化医疗创新的战略眼光。他拥有卓越的创业和管理能力，尤其擅长开创新业务。
加入腾讯之前，张猛曾在艾美仕市场研究公司担任中国区咨询业务负责人。任职期间，他成功领导完成了多个战略发展项目，并和医疗领域内多家企业和机构建立了紧密的合作关系，包括政府机构、跨国制药企业、医疗器械公司等。
加入艾美仕前，张猛曾在埃森哲纽约的生命科学业务部担任战略顾问，在产品定价和医保报销、新市场准入、市场竞争力分析、企业战略规划等方面积累了丰富的专业经验。此外，张猛还曾在美国强生负责业务开发，其间评估并落地重要三大战略联盟机会，通过外部技术引入，丰富产品组合。前往美国工作前，1997 至 1999 年间，张猛在中国西安杨森制药担任专业代表。
张猛拥有沃顿商学院医疗管理专业 MBA 学位，以及加拿大新布伦瑞克大学生物化学硕士学位，并于 1997 年获得南京大学生物学本科学位。

CEO Roundtable

Forum Documents

Agenda

Speakers